BMS joins off the shelf cancer therapy chase with Immatics’ T cell-engaging drug


Bristol Myers Squibb

Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and administer compared to earlier cell therapies.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.